Aprea Therapeutics Inc
NASDAQ:APRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aprea Therapeutics Inc
NASDAQ:APRE
|
US |
|
Wallbridge Mining Company Ltd
TSX:WM
|
CA |
Intrinsic Value
The intrinsic value of Aprea Therapeutics Inc (APRE) under the Base Case is 0.00203 USD per share.
Compared with the current market price of 0.45215 USD, the stock appears
Overvalued by 100% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Aprea Therapeutics Does
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications.
- Headquarters
- United States of America US
- Employees
- 8
- IPO date
- Oct 3, 2019
Revenue & Expenses Breakdown
Aprea Therapeutics Inc
Earnings Waterfall
Aprea Therapeutics Inc
The intrinsic value for Aprea Therapeutics Inc (APRE) under the Base Case is 0.00203 USD.
Compared with the current market price of 0.45215 USD, the stock appears Overvalued by 100% .